{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:02:31Z","timestamp":1789945351772,"version":"4.0.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.blre.2011.03.005","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T17:59:19Z","timestamp":1303235959000},"page":"181-191","source":"Crossref","is-referenced-by-count":47,"title":["Practical management of adverse events in multiple myeloma: Can therapy be attenuated in older patients?"],"prefix":"10.1016","volume":"25","author":[{"given":"Antonio","family":"Palumbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas F.","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2011.03.005_bb0005","series-title":"based on November 2009 SEER data submission, posted to the SEER website","article-title":"SEER Cancer Statistics Review 1975\u20132007","author":"Altekruse","year":"2011"},{"issue":"8","key":"10.1016\/j.blre.2011.03.005_bb0010","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3109\/10428194.2010.487959","article-title":"Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches","volume":"51","author":"Engelhardt","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.03.005_bb0015","author":"National Comprehensive Cancer Network (NCCN)"},{"issue":"26","key":"10.1016\/j.blre.2011.03.005_bb0020","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.blre.2011.03.005_bb0025","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2011.03.005_bb0030","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"9594","key":"10.1016\/j.blre.2011.03.005_bb0035","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"9513","key":"10.1016\/j.blre.2011.03.005_bb0040","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.blre.2011.03.005_bb0045","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.blre.2011.03.005_bb0050","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib\u2013melphalan\u2013prednisone\u2013thalidomide followed by maintenance with bortezomib\u2013thalidomide compared with bortezomib\u2013melphalan\u2013prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.blre.2011.03.005_bb0055","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.blre.2011.03.005_bb0060","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.blre.2011.03.005_bb0065","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood.V116.21.1940.1940","article-title":"A multicenter, open label study of oral lenalidomide and prednisone (RP) followed by oral lenalidomide melphalan and prednisone (MPR) and oral lenalidomide maintenance in newly diagnosed elderly multiple myeloma patients","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2011.03.005_bb0070","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.blre.2011.03.005_bb0075","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood.V116.21.622.622","article-title":"A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients >=65years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2011.03.005_bb0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2141.2008.07321.x","article-title":"Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma","volume":"143","author":"Lonial","year":"2008","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.blre.2011.03.005_bb0085","article-title":"Bortezomib and melphalan as part of VMP are associated with similar hematologic toxicity to MP alone [abstract]","volume":"9","author":"Richardson","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.blre.2011.03.005_bb0090","unstructured":"GlaxoSmithKline. Alkeran prescribing information. http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=35194#nlm34084-4. Accessed 17 August 2010."},{"key":"10.1016\/j.blre.2011.03.005_bb0095","unstructured":"Celgene. Lenalidomide summary of product characteristics.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000717\/WC500056018.pdf. Accessed 28 January 2011."},{"issue":"1","key":"10.1016\/j.blre.2011.03.005_bb0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.blre.2011.03.005_bb0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.blre.2008.07.003","article-title":"Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma","volume":"23","author":"Palumbo","year":"2009","journal-title":"Blood Rev"},{"issue":"Suppl 1","key":"10.1016\/j.blre.2011.03.005_bb0110","article-title":"Erythropoiesis-stimulating agents: no impact on long-term outcome in MM patients in the VISTA trial [abstract]","volume":"9","author":"Richardson","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.blre.2011.03.005_bb0115","author":"National Comprehensive Cancer Network (NCCN)"},{"key":"10.1016\/j.blre.2011.03.005_bb0120","author":"Medice Arzneimittel P\u00fctter GmbH & Co.KG"},{"key":"10.1016\/j.blre.2011.03.005_bb0125","author":"Amgen Europe"},{"issue":"11","key":"10.1016\/j.blre.2011.03.005_bb0130","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1182\/blood.V104.11.4914.4914","article-title":"Protective effect of VELCADE(R) on thalidomide associated deep vein thrombosis (DVT)","volume":"104","author":"Zangari","year":"2004","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2011.03.005_bb0135","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood.V116.21.307.307","article-title":"A phase III PETHEMA\/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib\/thalidomide\/dexamethasone) over TD and VBMCP\/VBAD plus bortezomib","volume":"116","author":"Rosi\u00f1ol","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2011.03.005_bb0140","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.V114.22.1873.1873","article-title":"Bortezomib does not increase thromboembolic risk in multiple myeloma and may offer a protective effect with thalidomide\/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens","volume":"114","author":"Zangari","year":"2009","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.blre.2011.03.005_bb0145","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","article-title":"American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer","volume":"25","author":"Lyman","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2011.03.005_bb0150","first-page":"20","article-title":"Improving clinical outcomes of venous thromboprophylaxis in multiple myeloma","volume":"2","author":"Iyengar","year":"2010","journal-title":"Online J Clin Audits"},{"issue":"2","key":"10.1016\/j.blre.2011.03.005_bb0155","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2011.03.005_bb0160","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2011.03.005_bb0165","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.03.005_bb0170","unstructured":"Celgene. Thalidomide summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000823\/WC500037050.pdf. Accessed 17 August 2010."},{"issue":"8","key":"10.1016\/j.blre.2011.03.005_bb0175","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2011.03.005_bb0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2011.03.005_bb0185","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"issue":"22","key":"10.1016\/j.blre.2011.03.005_bb0190","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2011.03.005_bb0195","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2011.03.005_bb0200","first-page":"133","article-title":"The evaluation of peripheral neuropathy. Part I: clinical and laboratory evidence","volume":"1","author":"Kelly","year":"2004","journal-title":"Rev Neurol Dis"},{"issue":"5","key":"10.1016\/j.blre.2011.03.005_bb0205","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2011.03.005_bb0210","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2011.03.005_bb0215","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1188\/10.CJON.E22-E28","article-title":"Patient perceptions associated with chemotherapy-induced peripheral neuropathy","volume":"14","author":"Tofthagen","year":"2010","journal-title":"Clin J Oncol Nurs"},{"issue":"1","key":"10.1016\/j.blre.2011.03.005_bb0220","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1634\/theoncologist.11-1-51","article-title":"A practical update on the use of bortezomib in the management of multiple myeloma","volume":"11","author":"San Miguel","year":"2006","journal-title":"Oncologist"},{"issue":"23","key":"10.1016\/j.blre.2011.03.005_bb0225","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2011.03.005_bb0230","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2011.03.005_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2011.03.005_bb0240","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.blre.2011.03.005_bb0245","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/FPC.0b013e3283436b45","article-title":"Genetic variation associated with bortezomib-induced peripheral neuropathy","volume":"21","author":"Favis","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.blre.2011.03.005_bb0250","unstructured":"Millennium Pharmaceuticals Inc. Velcade summary of product characteristics. Accessed 17 August 2010."},{"issue":"10","key":"10.1016\/j.blre.2011.03.005_bb0255","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.blre.2011.03.005_bb0260","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.blre.2011.03.005_bb0265","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2011.03.005_bb0270","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2011.03.005_bb0275","series-title":"Prescribing information. Cambridge, MA, USA","article-title":"VELCADE\u00ae (bortezomib) for injection","author":"Millennium Pharmaceuticals Inc","year":"2009"},{"issue":"33","key":"10.1016\/j.blre.2011.03.005_bb0280","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.03.005_bb0285","doi-asserted-by":"crossref","first-page":"1018a","DOI":"10.1182\/blood.V110.11.3477.3477","article-title":"Safety, tolerability, and pharmacology of bortezomib in cancer patients with renal failure requiring dialysis: results from a prospective phase 1 study [abstract]","volume":"110","author":"Mulkerin","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2011.03.005_bb0290","first-page":"295","article-title":"Analysis of plasma concentration of thalidomide in Japanese patients of multiple myeloma with renal dysfunction [in Japanese]","volume":"50","author":"Arai","year":"2009","journal-title":"Rinsho Ketsueki"},{"issue":"12","key":"10.1016\/j.blre.2011.03.005_bb0295","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1211\/0022357022241","article-title":"Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis","volume":"55","author":"Eriksson","year":"2003","journal-title":"J Pharm Pharmacol"},{"issue":"36","key":"10.1016\/j.blre.2011.03.005_bb0300","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2011.03.005_bb0305","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study","volume":"109","author":"Chanan-Khan","year":"2007","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.blre.2011.03.005_bb0310","first-page":"144","article-title":"Randomized phase 2 trial of bortezomib\u2013dexamethasone (VD) versus VD plus cyclophosphamide or lenalidomide in myeloma patients achieving stable disease after 4 cycles of VD as second-line treatment [abstract]","volume":"95","author":"Dimopoulos","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2011.03.005_bb0315","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1600-0609.2004.00272.x","article-title":"Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure","volume":"73","author":"Tosi","year":"2004","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2011.03.005_bb0320","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bbmt.2010.02.020","article-title":"Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency","volume":"16","author":"Tosi","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2011.03.005_bb0325","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2141.2004.04875.x","article-title":"Thalidomide in patients with multiple myeloma and renal failure","volume":"125","author":"Fakhouri","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2011.03.005_bb0330","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1365-2141.2003.04395_2.x","article-title":"Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia","volume":"122","author":"Harris","year":"2003","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2011.03.005_bb0335","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis","volume":"47","author":"Chen","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.blre.2011.03.005_bb0340","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.blre.2011.03.005_bb0345","article-title":"VMP results in fewer bone events and greater ALP increases versus MP in the VISTA study in front-line MM [abstract]","volume":"9","author":"Delforge","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.blre.2011.03.005_bb0350","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/asheducation-2009.1.566","article-title":"How to treat elderly patients with multiple myeloma: combination of therapy or sequencing","author":"Palumbo","year":"2009","journal-title":"Hematology"},{"issue":"Suppl 1","key":"10.1016\/j.blre.2011.03.005_bb0355","article-title":"Similar benefit in patients aged \u226575years versus <75years with VMP in first-line MM and bortezomib in relapsed MM [abstract]","volume":"9","author":"Kropff","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"Suppl 2","key":"10.1016\/j.blre.2011.03.005_bb0360","article-title":"A prospective randomized trial of bortezomib-melphalan-prednisone-thalidomide followed by continuous bortezomib-thalidomide for initial therapy of multiple myeloma: effect of age and co-morbidities [abstract]","volume":"95","author":"Palumbo","year":"2010","journal-title":"Haematologica"},{"issue":"Suppl 2","key":"10.1016\/j.blre.2011.03.005_bb0365","first-page":"144","article-title":"Phase 3b UPFRONT study: interim results from a community-based prospective randomized trial evaluating three bortezomib-based regimens in elderly, newly diagnosed multiple myeloma patients [abstract]","volume":"95","author":"Niesvizky","year":"2010","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2011.03.005_bb0370","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T11:24:28Z","timestamp":1592479468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X11000324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0268960X11000324"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2011.03.005","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}